Psoriasis Drugs Market 2022
New Study Reports “Psoriasis Drugs 2022 Global Market Opportunities, Challenges, Strategies and Forecasts 2030” has been Added on PMR.
Introduction/Report Summary:
This report provides in depth study of “Psoriasis Drugs” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. Psoriasis Drugs report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.
Psoriasis is a chronic inflammatory skin disease that occurs due to genetic disposition and environmental factors. Psoriasis is a systemic disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. On an average, psoriasis affects around 2 – 3% of the population globally.
Plaque psoriasis, being the number one and most common indication, held nearly 85% share of the US$ 11.37 Bn psoriasis drugs market in 2021, with the market estimated to expand at a CAGR of nearly 6.5% over the next ten years.
An array of agents exist for the symptomatic treatment of psoriasis. Patients with mild-to-moderate psoriasis typically receive topical treatments that modulate gene transcription, promote keratinocyte differentiation, and inhibit cell proliferation.
Click Here to get Free Sample Copy Of Psoriasis Drugs Market Report@ https://www.persistencemarketresearch.com/samples/25102
A number of innovative and advanced therapies for the treatment and management of psoriasis are under development, many of which have novel targets and mechanisms of action. Psoriasis is linked with a number of medical conditions inclusive of psoriatic arthritis, depression, and cardio metabolic syndrome. The most commonly occurring form of psoriasis is chronic plaque.
Common treatment methods of psoriasis include topical administration of vitamin D analogues, glucocorticoids, and phototherapy. Moderate to severe psoriasis often calls for systemic treatment.
Prevalence of psoriasis has displayed a growing trend over the past decade. Rising awareness initiatives regarding psoriasis disease and its management & treatment options, increasing reimbursement support, and growing research & development with the adoption of biologics and biosimilars are some of the factors responsible for impacting the psoriasis drugs market and aiding sales growth.
Company Profiles:
- Janssen Biotech, Inc.
- Novartis International Ltd.
- Amgen Inc
- Pfizer Inc.
- Takeda Pharmaceutical Company Ltd.
- Merck & Co, Inc.
- Abb Vie Inc.
- Eli Lilly and Company
- Boehringer Ingelheim GmbH
- Sun Pharmaceutical Industries Ltd
Request for Methodology@ https://www.persistencemarketresearch.com/methodology/25102
Key Takeaways from Market Study
- Topical products are expected to continue holding over one-third market value share through 2031, primarily because of clinically approved topical ointments, foams, and creams available for the management of inflammation and rash due to psoriasis.
- Efficiency of corticosteroids for skin irritability and inflammation makes corticosteroid the leading segment with over 34% of revenue share in 2021.
- Easy availability of psoriasis drugs in hospital pharmacies and large distribution networks of hospital chains make it the largest segment, with more than 39% market share.
- Plaque psoriasis is the most commonly occurring autoimmune disease, accounting for a revenue share of around 85% in 2021.
- Presence of a large number of manufacturers, rising public awareness, and easy availability of psoriasis drugs and treatment options make North America the leading regional market with over 27% market share in 2021.
“Growing adoption of combination therapy and favourable reimbursement support for psoriasis to drive market growth,” says an analyst of Persistence Market Research.
Market Competition
Companies such as Amgen and Sun Pharma have been strongly working toward the development of an extensive clinical pipeline and manufacturing of new product lines for the treatment of psoriasis.
- In December 2021, Amgen announced positive top-line results from the Otezla® (apremilast) Phase 3 DISCREET study in moderate to severe genital psoriasis.
- In September 2020, Sun Pharma announced the launch of ILUMYA® (tildrakizumab) for the treatment of plaque psoriasis, in Japan.
Similarly, other psoriasis drug manufacturers are also trying to maintain and strengthen their portfolios through collaborations with local players or distribution partners. All such recent developments related to companies manufacturing psoriasis drugs have been tracked by the team at Persistence Market Research, which are available in the full report.
Key companies operating in the psoriasis drugs market include Janssen Biotech Inc, Novartis International Ltd., Amgen Inc, Pfizer Inc., Takeda Pharmaceutical Company Ltd. Merck & Co, Inc., Abb Vie Inc., Eli Lilly and Company, Boehringer Ingelheim GmbH, and Sun Pharmaceutical Industries Ltd.
What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the psoriasis drugs market in its latest study, presenting historical demand assessment of 2016 – 2021 and projections for 2022 – 2031.
The research study is based on the product (topical, oral, and injectable), drug class (interleukin inhibitors, corticosteroids, anti-inflammatory, and tumor necrosis factor inhibitor), distribution channel (hospital pharmacies, retail pharmacies, and e-Commerce), and indication (guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, and plaque psoriasis), across seven key regions of the world.
Click Here to get This report@https://www.persistencemarketresearch.com/checkout/25102
Major Highlights of Psoriasis Drugs Report:
- Psoriasis Drugs analysis report offers an in-depth study of the potential market growth opportunities and challenges.
- The report dives deeper into the market and explains the dynamic factors bolstering market growth.
- The report deeply assesses the current, historical market size, market share, and revenue growth rates to offer accurate market projections for the forecast period.
- The report analyzes Psoriasis Drugs presence across major regions of the world.
- It determines the production & consumption capacities and demand & supply dynamics of each regional market.
- The report further illustrates the intense competition among the key market players and highlights their effective business expansion plans and strategies.
- It provides company overview and SWOT analysis of each of the market players.
You Can Read Also-
Intravenous (IV) Iron Drugs Market
Global Biological Drugs Market
About us:
PersistenceMarketResearch is an esteemed company with a reputation of serving clients across domains of information technology (IT), healthcare, and chemicals. Our analysts undertake painstaking primary and secondary research to provide a seamless report with a 360 degree perspective. Data is compared against rep/uted organizations, trustworthy databases, and international surveys for producing impeccable reports backed with graphical and statistical information.
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com